Pharmacological and structural characterization of vibostolimab, a novel anti-TIGIT blocking antibody for cancer immunotherapy

Pharmacological and structural characterization of vibostolimab, a novel anti-TIGIT blocking antibody for cancer immunotherapy

Background Vibostolimab is a humanized anti-T cell immunoreceptor with immunoglobulin (Ig) and ITIM domains (TIGIT) antibody was recently investigated in late-stage clinical trials. Vibostolimab was developed based on its specific binding property to the human and cynomolgus monkey TIGIT protein and...

Full description

Saved in:
Bibliographic Details
Main Authors: Hongmei Wang, Maribel Beaumont, Wendy Blumenschein, Laurence Fayadat-Dilman, Mingmei Cai, Jing Yuan, Douglas Wilson, Thierry O Fischmann, Jeanne Baker, Tanya Keenan, Daniel Malashock, Eunseon Ahn, Komal Pradhan, Jeffery Grein, Srishti Chakravorty, Soheila Bahmanjah, David Ban, Ellen Chien, Mark Hsieh, Todd Mayhood, Janica C Wong, Mark A McCoy, Sybil M G Williams, Wolfgang Seghezzi, Jin-Hwan Han
Format: Article
Language:English
Published: BMJ Publishing Group 2025-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/8/e008972.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/8/e008972.full

Similar Items